EGFR and cancer: Consistently, knockdown or inhibition of DUSP6 elevated phosphorylated ERK and reduced the viability of lung adenocarcinoma cells with either KRAS or EGFR oncogenic mutations, indicating that cancer cells with ERK hyperactivation with oncogene activation are addicted to DUSP high-expression for their viability.